Literature DB >> 8878586

Single-dose and steady-state pharmacokinetics of hypericin and pseudohypericin.

R Kerb1, J Brockmöller, B Staffeldt, M Ploch, I Roots.   

Abstract

Single-dose and steady-state pharmacokinetics of antivirally acting hypericin (H) and pseudohypericin (PH) were studied in 13 healthy volunteers by administration of St. John's Wort extract LI 160, a plantal antidepressant. Oral administration of 250, 750, and 1,500 micrograms of H and 526, 1,578, and 3,156 micrograms of PH resulted in median peak levels in plasma (Cmax) of 1.3, 7.2, and 16.6 micrograms/liter for H and 3.4, 12.1, and 29.7 micrograms/liter for PH, respectively. The Cmax and the area under the curve values for the lowest dose were disproportionally lower than those for the higher doses. A lag time of 1.9 h for H was remarkably longer than the 0.4-h lag time for PH. Median half-lives for absorption, distribution, and elimination were 0.6, 6.0, and 43.1 h after 750 micrograms of H and 1.3, 1.4, and 24.8 h after 1,578 micrograms of PH, respectively. Fourteen-day treatment with 250 micrograms of H and 526 micrograms of PH three times a day resulted in median steady-state trough levels of 7.9 micrograms/liter for H and 4.8 micrograms/liter for PH after 7 and 4 days, respectively; the corresponding Cssmax levels were 8.8 and 8.5 micrograms/liter, respectively. Kinetic parameters after intravenous administration of Hypericum extract (115 and 38 micrograms for H and PH, respectively) in two subjects corresponded to those estimated after an oral dosage. Both H and PH were initially distributed into a central volume of 4.2 and 5.0 liter, respectively. The mean distribution volumes at steady state were 19.7 liters for H and 39.3 liters for PH, and the mean total clearance rates were 9.2 ml/min for H and 43.3 ml/min for PH. The systemic availability of H and PH from LI 160 was roughly estimated to be 14 and 21%, respectively. Treatment with Hypericum extract, even in high doses, was well tolerated.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8878586      PMCID: PMC163478     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  16 in total

Review 1.  Antiretroviral therapy: strategies beyond single-agent reverse transcriptase inhibition.

Authors:  K J Connolly; S M Hammer
Journal:  Antimicrob Agents Chemother       Date:  1992-03       Impact factor: 5.191

2.  Photosensitization of aqueous model systems by hypericin.

Authors:  V Senthil; J W Longworth; C A Ghiron; L I Grossweiner
Journal:  Biochim Biophys Acta       Date:  1992-01-23

Review 3.  New drug treatments for HIV infection and AIDS. A review following the Seventh International Conference on AIDS, Florence 16-21 June 1991.

Authors:  G R Venning; G M Scott
Journal:  Br J Clin Pharmacol       Date:  1992-03       Impact factor: 4.335

4.  The importance of light in the anti-HIV effect of hypericin.

Authors:  J B Hudson; L Harris; G H Towers
Journal:  Antiviral Res       Date:  1993-02       Impact factor: 5.970

5.  Pharmacokinetics and tolerability of a microemulsion formulation of cyclosporine in renal allograft recipients--a concentration-controlled comparison with the commercial formulation.

Authors:  E A Mueller; J M Kovarik; J B van Bree; A E Lison; K Kutz
Journal:  Transplantation       Date:  1994-04-27       Impact factor: 4.939

6.  Chemiluminescent activation of the antiviral activity of hypericin: a molecular flashlight.

Authors:  S Carpenter; M J Fehr; G A Kraus; J W Petrich
Journal:  Proc Natl Acad Sci U S A       Date:  1994-12-06       Impact factor: 11.205

7.  Inactivation of the human immunodeficiency virus by hypericin: evidence for photochemical alterations of p24 and a block in uncoating.

Authors:  S Degar; A M Prince; D Pascual; G Lavie; B Levin; Y Mazur; D Lavie; L S Ehrlich; C Carter; D Meruelo
Journal:  AIDS Res Hum Retroviruses       Date:  1992-11       Impact factor: 2.205

8.  Photodynamic inactivation of infectivity of human immunodeficiency virus and other enveloped viruses using hypericin and rose bengal: inhibition of fusion and syncytia formation.

Authors:  J Lenard; A Rabson; R Vanderoef
Journal:  Proc Natl Acad Sci U S A       Date:  1993-01-01       Impact factor: 11.205

9.  Evaluation of the antiviral activity of anthraquinones, anthrones and anthraquinone derivatives against human cytomegalovirus.

Authors:  D L Barnard; J H Huffman; J L Morris; S G Wood; B G Hughes; R W Sidwell
Journal:  Antiviral Res       Date:  1992-01       Impact factor: 5.970

10.  Hypericin as an inactivator of infectious viruses in blood components.

Authors:  G Lavie; Y Mazur; D Lavie; A M Prince; D Pascual; L Liebes; B Levin; D Meruelo
Journal:  Transfusion       Date:  1995-05       Impact factor: 3.157

View more
  13 in total

1.  Alterations in cyclosporin A pharmacokinetics and metabolism during treatment with St John's wort in renal transplant patients.

Authors:  Steffen Bauer; Elke Störmer; Andreas Johne; Hagen Krüger; Klemens Budde; Hans-Hellmut Neumayer; Ivar Roots; Ingrid Mai
Journal:  Br J Clin Pharmacol       Date:  2003-02       Impact factor: 4.335

2.  Pharmacokinetics, safety, and antiviral effects of hypericin, a derivative of St. John's wort plant, in patients with chronic hepatitis C virus infection.

Authors:  J M Jacobson; L Feinman; L Liebes; N Ostrow; V Koslowski; A Tobia; B E Cabana; D Lee; J Spritzler; A M Prince
Journal:  Antimicrob Agents Chemother       Date:  2001-02       Impact factor: 5.191

3.  Evaluation of the in vitro inhibitory impact of hypericin on placental glutathione S-transferase pi.

Authors:  Ozlem Dalmizrak; Gulnihal Kulaksiz-Erkmen; Nazmi Ozer
Journal:  Protein J       Date:  2012-10       Impact factor: 2.371

Review 4.  Hypericum perforatum: a 'modern' herbal antidepressant: pharmacokinetics of active ingredients.

Authors:  Mario Wurglics; Manfred Schubert-Zsilavecz
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

5.  Saint John's wort: an in vitro analysis of P-glycoprotein induction due to extended exposure.

Authors:  M D Perloff; L L von Moltke; E Störmer; R I Shader; D J Greenblatt
Journal:  Br J Pharmacol       Date:  2001-12       Impact factor: 8.739

Review 6.  Drug interactions with St John's wort : mechanisms and clinical implications.

Authors:  Marcus Mannel
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606

7.  Undeclared exposure to St. John's Wort in hospitalized patients.

Authors:  Meret Martin-Facklam; Karin Rieger; Klaus-Dieter Riedel; Jürgen Burhenne; Ingeborg Walter-Sack; Walter E Haefeli
Journal:  Br J Clin Pharmacol       Date:  2004-10       Impact factor: 4.335

8.  Impact of cytochrome P-450 inhibition by cimetidine and induction by carbamazepine on the kinetics of hypericin and pseudohypericin in healthy volunteers.

Authors:  Andreas Johne; Elke S Perloff; Steffen Bauer; Jürgen Schmider; Ingrid Mai; Jürgen Brockmöller; Ivar Roots
Journal:  Eur J Clin Pharmacol       Date:  2004-09-15       Impact factor: 2.953

9.  Differential diagnosis of gallstones by using hypericin as a fluorescent optical imaging agent.

Authors:  Marlein Miranda Cona; Ye-Wei Liu; Antoine Hubert; Ting Yin; Yuan-Bo Feng; Peter de Witte; Etienne Waelkens; Yan-Sheng Jiang; Jian Zhang; Stefaan Mulier; Qian Xia; Gang Huang; Raymond Oyen; Yi-Cheng Ni
Journal:  World J Gastroenterol       Date:  2016-08-07       Impact factor: 5.742

Review 10.  'Atypical' antidepressants in overdose: clinical considerations with respect to safety.

Authors:  Nicholas A Buckley; Thomas A Faunce
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.